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during	their	 lifetime	and	the	average	age	at	diagnosis	 is	70	years.1 
Lung	cancer	accounts	 for	 the	highest	cancer-related	deaths	 in	 the	
United	 States,	 causing	 23%	 of	 all	 cancer-related	 deaths	 which	 is	
more	than	colon,	breast,	and	prostate	cancers	combined.1	The	five-
year	survival	rate	of	all	lung	cancer	diagnoses	is	19%,	which	is	lower	





die within one year. It is also estimated that lung cancer care may be 
increased	to	173	billion	dollars	in	2020	in	the	United	States.2




ment. The two main types of lung cancer are small cell lung can-
cer,	accounting	for	15%	of	all	cases,	and	non-small	cell	lung	cancer	
(NSCLC)	which	is	any	type	of	epithelial	lung	cancer,	and	accounts	for	
80%	to	85%	of	all	cases	(Figure	1).3 The three most common histo-
logical	forms	of	NSCLC	are	epidermoid	or	squamous	cell	carcinoma,	
















Molecular	 features	 of	 NSCLC	 tumors	 may	 not	 only	 predict	 the	





enhances cell survival and stimulates proliferation.10 The most 
common	 mutations	 of	 EGFR	 are	 in-frame	 deletions	 of	 exon	 19,	
and	the	second	most	common	EGFR	mutation	is	single	nucleotide	
substitutions	L858R	in	exon	21.11 The most common mutation de-
tected	after	treatment	with	EGFR	inhibitors	is	T790M	in	exon	20	
which can confer drug resistance.12	The	third	most	frequent	muta-
tions	occur	in	KRAS,	accounting	for	15%-25%	of	cases.13 Usually 
mutations	 in	 KRAS	 and	 EGFR	 are	 mutually	 exclusive	 and	 non-
overlapping.	Another	common	molecular	feature	of	NSCLC	is	the	
presence of ALK	 fusion	gene,	which	encodes	a	receptor	tyrosine	
kinase	not	normally	expressed	in	the	lung.13	At	least	nine	different	
variants	 of	 fusion	 of	 ALK	with	 an	 upstream	 partner	 EML4	 have	
been	 identified	 causing	 constitutive	 activation	 of	 the	 kinase.13 
The	HER2	protein,	a	HER	family	receptor	tyrosine	kinase,	is	over-
expressed	 in	20%	of	all	NSCLC	and	gene	amplification	occurs	 in	
2%.14,15 These mutations commonly lead to constitutive activation 
of	the	HER2	signaling	pathway.16	Mutations	in	the	main	catalytic	
subunit,	PIK3CA,	of	phosphatidylinositol	3-kinase	occur	 in	about	





     |  3 of 18PETREK and YU
2%	of	NSCLC	cases.17	These	 tumors	can	activate	 the	protein	ki-
nase	B	signaling	pathway	without	growth	factors.	Protein	kinase	B	
is encoded by AKT1,	which	is	mutated	from	a	glutamate	to	a	lysine	
at	position	17	in	1%	of	NSCLC	cases	and	causes	PI3K-independent	
activation	of	protein	kinase	B.18,19	BRAF	is	a	member	of	the	RAF	
kinase	 family	 which	 confers	 signaling	 of	 the	MAPK	 family	 from	
the	RAS	GTPases	to	control	cell	proliferation.20	BRAF	mutations	




Amplification	 of	 the	 gene	MET,	which	 codes	 hepatocyte	 growth	
factor	receptor	(HGFR)	causes	resistance	to	EGFR	tyrosine	kinase	




Lung	 cancer	 that	 is	 diagnosed	 at	 the	 early	 stages	 is	 commonly	
treated	 with	 resection	 surgery	 or	 lobectomy,	 chemotherapy,	
and	 radiation.	 Surgery	may	 range	 from	 removing	 an	 entire	 lung	
to	 removing	 part	 of	 a	 lobe,	 depending	 on	 the	 size	 and	 location	





a	 larger	 dose,	 around	 22	 Gray,	 in	 usually	 fewer	 than	 5	 doses.24 
Brachytherapy,	or	 internal	 radiation	 therapy,	 involves	 the	 insert-
ing a radioactive pellet in or near the tumor for a short amount of 
time	or	permanently.	The	radiation	stays	localized	and	gets	weaker	
over	time.	Radiofrequency	ablation	uses	radio	waves	emitted	from	
a probe guided by a computed tomography scan.
Molecular	medicine	or	pharmacotherapy	spans	from	chemotherapy	
to	targeted	therapy	and	the	most	recent	immunotherapy,	which	utilize	
small-molecule	 and	 protein	 or	 antibody	 drugs	 (Table	 2).	 Commonly	
used	 chemotherapies	 for	 the	 treatment	 of	NSCLC	 include	 cisplatin,	
carboplatin,	 docetaxel,	 paclitaxel,	 pemetrexed,	 and	 vinorelbine	 that	
usually	interfere	with	DNA	synthesis	or	replication	to	achieve	the	inhi-
bition	of	cancer	cell	proliferation	and	growth	(Table	2).	Nevertheless,	
chemotherapy may not be effective for all patients and many cancers 











therapies is generally consistent across subtypes with higher rates for 
tumors with high mutational burden. The effectiveness of two anti-
body	drugs,	anti-VEGF	bevacizumab	and	anti-VEGFR	ramucirumab,	is	














mary	or	acquires	resistance	29,30 or show severe adverse effects such 
as diarrhea and pneumonitis.31-33	In	addition,	targeted	therapies	have	
the	greatest	 response	 rate	 for	patients	with	 the	 indicated	mutation,	
therefore,	due	to	the	high	heterogeneity	of	mutations	within	NSCLC,	










tion or translation inhibition 34	(Figure	2).	The	biogenesis	of	miRNAs	
starts	with	 the	 transcription	 of	miRNA-coding	 genes	 into	 primary	
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TA B L E  2  List	of	drugs	approved	in	the	US	for	the	treatment	of	NSCLC	and	their	molecular	targets	or	mechanistic	actions
Treatment Classification Target or Action Approval Overall Response Rate
Bevacizumab antibody/protein VEGF Non-squamous	NSCLC 35%	with	carboplatin	and	
paclitaxel	150
Ramucirumab antibody/protein VEGFR Metastatic	non-squamous	
NSCLC
23%	with	docetaxel	151
Erlotinib small molecule EGFR EGFR	L858R	mutation,	
metastatic	NSCLC
74.4%	152
















Crizotinib small molecule ALK/CD246,	ROS Advanced	or	metastatic	
ALK-positive	NSCLC
74%	156
Ceritinib small molecule ALK/CD246 Metastatic	ALK-positive	
NSCLC
58%	157
Brigatinib small molecule ALK/CD246 Metastatic	ALK-positive	
NSCLC
71%	158
Alectinib small molecule ALK/CD246,	RET Metastatic	ALK-positive	
NSCLC
82.9%	159




Trametinib small molecule MEK Metastatic	NSCLC	with	B-
Raf	V600E	mutation
See	dabrafenib
Entrectinib small molecule ROS1/NTRK	fusion Metastatic,	ROS1/NTRK-
positive	NSCLC
78%	161





Pembrolizumab antibody/protein PD-1/CD279 Advance	or	metastatic	squa-
mous	NSCLC
44.8%	163






Ipilimumab antibody/protein CTLA4/CD152 Metastatic	NSCLC 45.3%	with	nivolumab	165
Carboplatin & 
cisplatin




Irinotecan small molecule Topoisomerase I Advanced	NSCLC 43.7%	with	cisplatin	167
Etoposide small molecule Topoisomerase II Metastatic	NSCLC 21.9%	with	cisplatin	168





Paclitaxel small molecule Tubulin; inhibition of mitosis Advanced	or	metastatic	
NSCLC
See	carboplatin	&	cisplatin
Vinorelbine small molecule Tubulin; inhibition of mitosis Advanced	NSCLC 43%	with	cisplatin	170
(Continues)
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miRNA	 (pri-miRNA)	 transcripts.	 The	 pri-miRNA	 is	 thus	 processed	





among which the guide strand is preferably incorporated into the 
RNA-induced	silencing	complex	(RISC)	consisting	of	the	Argonaute	




Many	 miRNAs	 are	 involved	 in	 the	 control	 of	 target	 gene	 ex-
pression	 behind	 various	 cancer	 cellular	 processes	 (see	 the	 follow-
ing	 section),	 exhibiting	 tumor	 suppressive	 or	 promotive	 activities.	
Specifically,	a	miRNA	that	reduces	the	expression	of	tumor	suppres-
sors	acts	as	a	tumor	promotor,	and	a	miRNA	that	degrades	oncogene	
transcripts	 functions	 as	 a	 tumor	 suppressor.	 Interestingly,	 some	
miRNAs	 are	 dysregulated	 in	NSCLC	 (Table	 3)	 that	may	 be	 indica-
tive	 of	 disease	 status	 or	 therapeutic	 outcome.	With	 some	 excep-




the magnitude of dysregulation varies by case. Dysregulation of 
miRNA	expression	may	be	caused	by	different	mechanisms	such	as	
chromosomal	deletion	or	methylation,	or	dysregulation	of	their	tran-
scription	 factors,	 enzymes,	 or	 binding	proteins	 involved	 in	miRNA	
biogenesis.	Dicer,	the	RNase	responsible	for	the	processing	of	pre-
miRNAs,	 is	 essential	 for	mouse	 development	 and	 stem	 cell	 main-
tenance.38 Dicer was reported to be downregulated in some lung 
cancer	patients,	leading	to	a	global	decrease	in	miRNAs	and	associ-
ated	with	poor	prognosis,39 and conditional deletion of Dicer led to 
increased lung tumorigenesis in mice.40	Actually,	the	role	of	Dicer	in	









might	 be	 involved	 in	 tumor	 initiation	 and	 progression.	 Ultimately,	
Treatment Classification Target or Action Approval Overall Response Rate
Vinblastine small molecule Microtubule;	inhibition	of	
mitosis
Advanced	NSCLC 41%	with	cisplatin	171
Pemetrexed small molecule Thymidylate	synthase,	dihy-
drofolate reductase
Advanced	NSCLC 9.1 in patients previously 
treated with chemother-
apy 172
Gemcitabine small molecule Inhibition	of	DNA	synthesis Advanced	or	metastatic	
NSCLC
40.6%	with	cisplatin	168
TA B L E  2   (Continued)
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an	 epithelial-like	 cell	 loses	 its	 attachment	 to	 the	 basal	membrane	
and	assumes	mesenchymal	characteristics	 like	greater	motility	and	
invasiveness.	EMT	allows	for	cancer	cells	to	metastasize	by	migrat-
















the	 transcription	 factor	FOXM1	to	 reduce	 invasion	 in	H1299	cells	
as	determined	by	Matrigel	invasion	assay.52	In	addition,	miR-186-5p	
targets	 CDC42	 leading	 to	 the	 inhibition	 of	 migration	 and	 related	
EMT	processes.53	Likewise,	dysregulation	of	these	miRNAs,	as	evi-
dent	in	NSCLC,	leads	to	greater	EMT	and	a	more	invasive,	migratory,	
and potentially metastatic phenotype.
5.2 | Signal transduction in lung cancer survival and 
proliferation
Oncogenesis	 is	 driven	 by	 an	 over-expression	 or	 activation	 of	
growth	 signaling,	 such	 as	 growth	 factors,	 receptors,	 or	 down-
stream	 signaling	molecules.	 Growth	 factor	 ligands	 bind	 to	 their	
corresponding receptors to relay a signal and induce prolif-
eration.	 Cancer	 cells	 can	 hijack	 signaling	 by	 over-expressing	 or	
mutating growth factor receptors to increase proliferative sig-
nals	 and	miRNAs	 target	 certain	 receptor	 to	modulate	 signaling.	
miRNA Expression Direct Targets Verified References
miR-124-3p Decreased STAT-3,	MYO10,	SMAD4 [173-176]
























miR-451a-5p Decreased PSMB8,	RAB14 [175,180,211]
miR-21-5p Increased PTEN [180,212]
miR-210-3p Increased E2F3,	NDUFA4,	SDHD [79,213]
miR-205-5p Increased PTEN,	PHLPP2,	ITGα5 [131,214-216]




miR-182-5p Increased PDCD4,	RGS17 [213,221-223]
miR-183-5p Increased FOXO1,	VIL2 [134,213,224]
TA B L E  3  List	of	miRNAs	most	
commonly	dysregulated	in	NSCLC	and	
some of their corresponding targets 
validated	by	biological	experiments
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miR-7-5p,54	 miR-133b-3p,55	 miR-134-5p,56	 and	 miR-200a-3p	 57 
target	epidermal	growth	 factor	 (EGFR)	 (Figure	3),	which	 is	 com-
monly	 overexpressed	 in	 NSCLC	 (Table	 1),	 to	 alter	 downstream	







kit	among	others.60	miR-152-3p	 targets	 fibroblast	growth	 factor	
2	 (FGF2)	 65	 and	miR-99b-5p	 66	 and	miR-100-5p	 67 target fibro-
blast	growth	factor	receptor	3	(FGFR3).	MET	is	a	receptor	for	the	
hepatocyte	growth	factor	 (HGF)	and	 is	 targeted	by	a	number	of	
miRNAs	 including	miR-130a-3p,68	miR-449a-5p	69	miR-34a-5p,70 
miR-200a-3p,57	 miR-206-3p,71	 miR-31-5p,72	 miR-139-5p,73	 miR-













binding	 to	 VEGF	 receptor	 (VEGFR)	 or	 neuropilin	 (NRP).76 During 
normal	conditions,	 tumor	suppressor	von	Hippel	Lindau	 (vHL)	me-
diates	the	degradation	of	hypoxia-inducible-factor-1	(HIF1)	through	
the	 ubiquitin-proteasome	pathway.	By	 contrast,	HIF-1α associates 
with	HIF1β	 during	 hypoxia	 and	 thus	 increases	VEGF	 transcription	
by binding to the promoter.76	 miRNAs	 regulate	 many	 important	
factors	 of	 angiogenesis	 (Figure	 3).	 For	 example,	 miR-126-3p	 and	
miR-128-3p,	 both	 of	 which	 are	 commonly	 decreased	 in	 NSCLC,	
directly	 target	 VEGF-A	 and	 VEGF-C,	 respectively,	 to	 decrease	









HIF1α may reduce angiogenesis essential for tumor progression




lizing	HIF1α to promote angiogenesis and increase glycolysis.79	miR-
21-5p	directly	targets	PTEN	and	activates	AKT	and	ERK1/2	which	
leads	to	higher	levels	of	HIF1α	and	VEGF	expression.80	miR-378-5p	
is	 over-expressed	 in	 NSCLC	 tumors	 in	 patients	 with	 brain	metas-
tasis	 and	 leads	 to	 increased	VEGF	 expression	 and	 angiogenesis.81 
miR-206-3p	directly	 suppresses	 the	expression	of	protein	14-3-3ζ 
which	 consequently	 decreases	 VEGF,	 HIF1α,	 and	 phosphorylated	
STAT3	and	results	in	a	lower	degree	of	angiogenesis	as	assayed	by	
HUVECs	recruitment	as	well	as	 inhibition	of	 intratumoral	capillary	
tube formation in vivo.82	In	one	study,	coculture	of	NSCLC	cell	lines	
with	vascular	endothelial	cells	leads	to	higher	levels	of	miR-494-3p	
in	 the	 vascular	 endothelial	 cells,	 in	 addition,	 a	miR-494	 antagomir	
decreases	 tumor	 vascularization,	 suggesting	 that	 miRNAs	may	 be	




The cell cycle is altered among almost all cancer cells to allow for 
uncontrolled	growth.	Cyclins	and	cyclin-dependent	kinases	(CDKs)	
are partly responsible for entry into the different cell cycle stages. 
G1	begins	with	cyclins	D1,	D2,	and	D3	associating	with	CDK4	and	






dysregulated,	 and	 some	 are	 direct	 targets	 of	 particular	miRNAs	
(Figure	4	and	Table	3).	Tumor	suppressive	miR-34a-5p	directly	tar-
gets	CCND1	and	CDK6,	 leading	 to	 the	arrest	of	 the	cell	cycle	 in	
G1 phase.
89	 Furthermore,	miR-15a-5p	 and	miR-16-5p,	 down-reg-
ulated	 in	 NSCLC,	 directly	 targets	 CCND1,	 CCND2,	 and	 CCNE1,	




In	 addition,	 miR-30d-5p	 targets	 CCNE2,92	 miR-186-5p	 targets	
CCND1,	CDK2,	and	CDK6,93	and	miR-129-5p	targets	CDK6	94 to 
arrest	the	cells	 in	G1.	Generally,	cell	cycle-regulating	miRNAs	ex-
hibit tumor suppressive actions by targeting cell cycle promotive 
genes to induce a cancer cell cycle arrest.
5.5 | Evading Apoptosis
Cell	 death	mechanisms,	 including	 apoptosis	 or	 necrosis,	 are	 im-
portant	 for	 cells	 to	 maintain	 homeostasis,	 and	 dysregulation	 of	
these	pathways	leads	to	an	alteration	of	cell	proliferation,	includ-
ing	NSCLC	cells.	Some	miRNAs	regulate	certain	proteins	involved	
in	 cell	 death	 (Figure	 5),	 and	 dysregulation	 of	 such	miRNAs	may	
make	the	cells	evade	death	signals	and	continue	to	proliferate.	In	
brief,	apoptosis	occurs	when	a	death	ligand,	such	as	tumor	necro-
sis	 factor	 (TNF)-related	 apoptosis-inducing	 ligand	 (TRAIL),	 binds	
to	a	death	receptor,	 including	TNF	receptors	1	and	2	(TNFR1/2),	
causing	 receptor	multimerization	and	activation	of	 the	death	 in-
duced	 signaling	 complex	 (DISC).95 This can result in direct acti-
vation	 of	 caspase-8	 mediated	 cleavage	 of	 effector	 caspases,	
like	 caspase-3,96	 or	 caspase-8	 cleavage	 of	 Bid	 which	 releases	
mitochondrial	 cytochrome	 c	 to	 associate	with	 Bax	 and	 Bak	 and	
forms the apoptosome and cleaves effector caspases.97	 BCL2,	
an	anti-apoptotic	protein	 that	mainly	 functions	 to	 inhibit	 release	
of	 cytochrome	 c	 from	 the	 mitochondria,98	 is	 targeted	 by	 miR-
181-5p,99	miR-7-5p,100	miR-503-5p,101	miR-200bc/429	 cluster,102 
and	miR-497-5p	103	(Figure	5).	In	addition,	BCL2L2	and	BCL6,	also	
anti-apoptotic	 proteins,	 are	directly	 targeted	by	miR-15a-5p	 and	
miR-187-3p,	 respectively,	 to	 enhance	 apoptosis.104,105	 TRAIL	 ex-
pression	 induces	 apoptosis;	 however,	 NSCLC	 can	 confer	 resist-
ance	 to	 TRAIL-mediated	 apoptosis	 through	 many	 mechanisms	
including	 loss	of	PTEN	and	constitutive	activation	of	AKT	 106 or 
increased	matrix	metalloproteases.107	Therefore,	over-expression	





This causes dysregulation of the cell 
cycle and ultimately increases cancer cell 
proliferation. Restoration of such tumor 
suppressive	miRNAs	may	lead	to	cell	cycle	
arrest to achieve anticancer effects
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of	 miR-148a-3p	 can	 sensitize	 NSCLC	 to	 TRAIL	 by	 targeting	
MMP15.108	miR-221-3p	and	miR-222-3p	can	confer	TRAIL	resist-
ance	by	targeting	tumor	suppressors	PTEN	and	tissue	inhibitor	of	





Some	 miRNAs	 can	 alter	 the	 metabolic	 potential	 of	 cancer	 cells.	 A	
higher metabolic rate may enhance the tumorigenesis and growth of 
NSCLC	 cells.	 miR-155-5p	 promotes	 aerobic	 glycolysis	 by	 indirectly	
upregulating	HK2,	as	determined	by	a	hexokinase	colorimetric	assay	
as	well	 as	glucose	and	L-lactate	 test	kits.111 The increase in glycoly-
sis	leads	to	greater	degree	of	cell	viability.	miR-143-3p	directly	targets	
HK2,	the	first	rate-limiting	enzyme	in	glycolysis,	to	decrease	glycolysis	
and proliferation as well as tumorigenesis in vivo.112	miR-124-3p	over-











chondrial membrane potential that are phenotypic of mitochondria 
dysfunction.79	miR-145-5p	and	miR-138-5p	directly	 target	phospho-
inositide-dependent	protein	kinase-1	(PDK1),	an	important	enzyme	in	






pies	 including	 chemotherapy	 and	 radiation	 therapy.	 For	 instance,	
upregulation	of	miR-21-5p	leads	to	a	reduction	of	apoptosis	and	de-
crease	of	sensitivity	to	two	chemotherapeutics,	docetaxel	and	cispl-
atin.110	 Induced	by	 radiation,	miR-155-5p	does	 confer	 resistance	 to	
radiation	 therapy	 by	 indirectly	 increasing	 HK2	 to	 promote	 aerobic	
glycolysis.111	Furthermore,	chronic	treatment	with	EGFR	inhibitor	ge-
fitinib	 reduces	 the	 expression	of	miR-155-5p	 and	miR-200c-3p	 and	
may decrease the sensitivity to gefitinib.118	 Therefore,	miRNA	pro-
files from tissue or body fluids may also be used as predictive bio-
markers	for	the	sensitivity	of	NSCLC	tumors	to	certain	therapies	and	
to	determine	optimal	 therapies	 for	 the	 treatment	of	NSCLC.	As	 an	
















Understanding	miRNA-controlled	 regulation	may	 not	 only	 improve	
the understanding of multidrug resistance mechanisms but also offer 





for implantation in vivo. While this does not necessarily model 
therapeutic	potential	 of	miRNAs,	 it	 does	provide	 important	 in-
formation	beyond	cell-based	findings	regarding	the	 importance	
of	miRNAs	 in	 the	 control	 of	 tumor	 initiation	 and	 development	
or	 tumorigenesis	 (Table	4).	For	example,	 subcutaneously	or	 tail	
vein	 injected	 A549	 cells	 expressing	 miR-124-3p,	 miR-126-3p,	
miR-143-3p,	miR-34a-5p,	 Let-7b-5p,	 or	miR-182-5p	 showed	 re-
duced tumor growth and in some cases reduce lung metastasis 
F I G U R E  5  miRNAs	affect	the	ability	to	evade	of	apoptosis.	
BCL6,	BCL2L2,	and	BCL2	are	anti-apoptotic	as	they	inhibit	
cytochrome c release from the mitochondria. Dysregulation or 
malfunction	of	miRNAs	in	NSCLC	that	inhibit	the	anti-apoptotic	
cascade may reduce apoptotic capacity and enhance cancer 
progression.	Therefore,	restoration	of	such	miRNA	expression	or	
function represents a novel therapeutic strategy
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as	 compared	 to	 control	 cells.	 Lewis	 lung	 carcinoma	 cells	 tran-
siently	transfected	with	miR-101-3p	displayed	a	smaller	increase	
of tumor volume over time when subcutaneously injected into 
the	flank	of	mice,	as	well	as	a	reduction	of	metastasis	to	the	lung	
when intraperitoneally injected.127	 Cells	 overexpressing	 miR-
145-5p	or	miR-486-5p	subcutaneously	implanted	or	tail	vein	in-
jected in mice displayed a slower rate of tumor growth.62,128	Lung	
cancer	cells	344SQ	transfected	with	miR-200a-3p	or	miR-200b-
5p or both showed smaller tumor volume with transfection of 
both	miRNAs	having	the	greatest	 impact.129	By	contrast,	trans-




H460	 cells	 overexpressing	 miR-205-5p	 grew	 faster	 and	 led	 to	
greater	tumor	volume	and	vascularization,	as	compared	to	con-
trol cells.131	 Compared	 to	 corresponding	 controls,	 overexpres-
sion	of	miR-31-5p	in	three	different	lung	cancer	cell	lines,	H1993,	
H1437,	and	H460,	led	to	an	increase	in	subcutaneous	tumor	vol-
ume.132 The same study also demonstrated that transgenic mice 
with	 a	 doxycycline-inducible	miR-31-5p	 expression	 in	 the	 lung	
exhibited	greater	levels	of	hyperplasia	and	adenomas.132 In con-
clusion,	ectopic	or	overexpression	of	certain	functional	miRNAs	
can	 largely	 influence	 the	 tumorigenesis	 of	 NSCLC	 cells,	 which	





Two	 miRNA-based	 therapeutic	 strategies	 have	 been	 established,	
aiming	to	restore	tumor	suppressive	miRNAs	and	inhibit	tumor	pro-
motive	miRNAs,	 respectively.	Many	 studies	 were	 thus	 conducted	
to	define	the	effectiveness	of	specific	miRNA	therapeutics	for	the	
treatment	of	NSCLC	in	animal	models	in	vivo	(Table	5).	AntagomiRs	
were	 employed	 for	 the	 inhibition	 of	 tumor	 promotive	 miR-21-5p,	




sion	of	NSCLC	 in	vivo.136	Synthetic	miR-34a-5p	 injected	either	 in-
tratumorally or through the tail vein was effective in inhibiting the 
growth	of	 subcutaneous	xenograft	NSCLC,137 and it did not show 
major	 impact	on	the	cytokine	profiles	or	 liver	or	kidney	functions.	
A	 specific	 type	 of	 chemical	 modification	 of	 miR-145-5p,	 namely	
locked	nucleic	acid,	delivered	with	a	polyurethane-short	branched-
polyethylenimine,	 led	to	significant	inhibition	of	tumor	growth	and	
the effects were enhanced by radiation and cisplatin therapy.138 
Orthotopic	 NSCLC	 tumor	 growth,	 metastasis,	 and	 vascularization	
were	 decreased	 in	 mice	 treated	 with	 miR-200a/b.129	 miR-29b-3p	
decreased cell proliferation and increased apoptosis in subcutane-
ous	NSCLC	tumors.139	Combination	treatment	with	miR-34a-5p	and	
TA B L E  4  Some	miRNAs	shown	to	affect	tumorogenesis	of	NSCLC	cells	in	animal	models
miRNA Cell line Mouse strain Finding Reference
miR-124-3p A549 nude	BALB/c Reduced lung metastasis from tail vein 
injected cells
[176]
miR-126-3p A549 nude	BALB/c Reduced tumor wieght [77]
miR-143-3p A549 nude	BALB/c Reduced tumor wieght [225]
miR-34a-5p A549 nude	BALB/c Reduced	tumor	wieght,	and	lung	tumor	
metastasis
[226]
let-7b-5p A549,	H460 nod/scid Reduce tumor growth [227]
miR-101-3p LLC C57BL/6 Reduced	tumor	wieght,	metastasis	from	IP	
injected cells
[127]
miR-100-5p SPC-A1/DTX nude Reduced tumor volume in response to 
docetaxel
[201]
miR-145-5p A549	CIC nude Reduced tumor volume [128]
miR-486-5p H460-luc2 athymic	Swiss Reduced lung metastasis from tail vein 
injected cells
[62]
miR-451-5p A549 nude	BALB/c Reduced tumor volume in respose to 
cisplatin
[228]
miR-21-5p CAG-miR-21;K-rasLA2 Reduced tumor burden and increased 
survival
[130]
miR-205-5p H460 BALB/c Reduced tumor volume [131]
miR-31-5p H1993/	H1437/H460 nude Reduced tumor volume [132]
miR-200a/b 344SQ nude Reduced tumor volume [129]
miR-182-5p A549 nude Reduced tumor volume and weight and 
increased survival
[229]
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or	miR-124-3p	molecules	 produced	 in	 bacteria	 and	delivered	with	
in	 vivo-jetPEI	 into	 tumor-bearing	 mouse	 models	 decreased	 the	
growth	of	both	subcutaneous	and	metastatic	NSCLC	tumors,	with	
minimal	 influence	on	 blood	 chemistry	 or	 cytokine	 profiles,	 in	 two	
different studies.144,145	A	variety	of	different	delivery	methods	have	
been	tested	in	vivo	to	deliver	the	above-mentioned	miRNAs.	Many	
miRNAs	 were	 formulated	 with	 lipid-based	 technologies,	 such	 as	
liposomes,	 lipoplex,	 siPORTamine,	 and	MaxSuppressor,	which	 sur-
round	the	RNA	and	protect	it	from	degradation.136,137,139,140,146	Viral	
vectors,	such	as	lentivirus	or	adenovirus,	as	well	is	positively	charged	
polyethylenimine,	 which	 associates	 with	 the	 negatively	 charged	
RNA,	were	also	used.134,136,138,144,145	 In	most	 cases,	miRNA	 thera-
peutics	 were	 administered	 through	 the	 tail	 vein	 or	 intra-tumoral	
injection.	These	in	vivo	findings	demonstrate	the	promise	of	miRNA-
based	therapies	for	the	treatment	of	NSCLC.







TA B L E  5  Some	miRNA-based	therapies	for	the	treatment	of	NSCLC	assessed	in	animal	models	in	vivo










siPORTamine	(lipid	based) Decreased proliferation [136]
let-7a-5p
(lenti-let-7)
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experienced	 immune-related	 adverse	 effects	 where	multiple	 deaths	
also	occurred	with	complex	and	uncertain	causes.	The	most	common	
adverse	effects	were	fever,	fatigue,	nausea,	diarrhea,	and	vomiting,	and	






immune system. The termination of this trial reiterates the importance 
of safety study in addition to efficacy during drug development.
9  | CONCLUSIONS AND PERSPECTIVES
Functional	miRNAs	derived	 from	 the	human	genome	are	 critical	
factors	 in	 posttranscriptional	 regulation	 of	 target	 gene	 expres-
sion	 underlying	 many	 cellular	 processes,	 including	 metabolism,	





motive	 miRNAs	 are	 commonly	 upregulated.	 With	 the	 improved	
understanding	 of	 miRNA	 biology	 in	 NSCLC,	 new	 miRNA-based	
therapies	 are	 under	 active	 investigations,	 in	 particular,	 the	 res-
toration	 of	 tumor	 suppressive	 miRNAs	 and	 inhibition	 of	 tumor	
promotive	 miRNAs.	 Nevertheless,	 many	 challenges	 remain	 for	
the	development	of	new	therapeutics.	Although	a	number	of	RNA	




riers. Chemical modifications and formulation with biocompatible 










questions:	whether	 the	drug	 is	effective	against	 the	disease	and	
whether	 the	 drug	 is	 safe	 for	 the	 patients,	which	warrants	more	
extensive	studies.
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